CSM molecules portfolio consists of around 25 molecules currently. The company is in advanced stages for around five to six molecules, which are expected to get commercialised in the next fiscal. This should boost order book growth further in years to come. The order backlog remains at $1.5 billion at present, which provides revenue visibility for the next three years at least. Going ahead, since the new MPP is expected to get commissioned by Q4FY21 along with two new MPPs that are planned to come on board by next fiscal, we expect better execution to lead to strong topline growth in...